Quarterly Financial Results for Q2 2026: This 10-Q filing covers Charles River Laboratories' financial performance for the second quarter ended June 27, 2026, including consolidated statements of operations, balance sheets, and cash flow statements comparing current quarter and year-to-date results to prior year periods. Segment Performance Data: The filing contains financial information broken…

Our analysis rates this filing BEARISH. Charles River Laboratories faces elevated execution risk from an unusually aggressive portfolio transformation in H1 2026. The company is simultaneously divesting two material business units while integrating two acquisitions—a level of transaction velocity…

Concern level: HIGH (7.2/10). Key factors: Substantial Business Restructuring (severity 8/10): Simultaneous execution of 2 major divestitures and 2 acquisitions within 6-month period (Jan-May 2026) creates unprecedented execution risk and management distraction; Significant Portfolio Divestitures (severity 7/10): European Discovery Services and CDMO/Cell Solutions business units divested in May…

Notable risk changes: Two major business unit divestitures completed in Q2 2026 (European Discovery Services on 5/22/26 and CDMO/Cell Solutions on 5/6/26) - representing significant portfolio restructuring and revenue base reduction; Pathoquest acquisition integration underway (closed 4/17/26) with identified customer relationships and developed technology intangibles requiring successful integration to justify…

The model predicts CRL will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.